Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM5A | P29375 | 3/20 | 0.42 |
| ▸ | LTA4H | P09960 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | DUT | P33316 | 1/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31399552 | 0.93 | MEN1 (0.46) | MEN1KMT2AKDM5ALTA4HTSHR | |
| SCHEMBL839062 | 0.86 | TSHR (0.48) | MEN1KMT2ATSHRALDH1A1LMNA | |
| SCHEMBL25345807 | 0.85 | LMNA (0.47) | KMT2ATSHRALDH1A1LMNADUT | |
| SCHEMBL1246160 | 0.85 | LMNA (0.47) | KMT2ATSHRALDH1A1LMNADUT | |
| SCHEMBL11635954 | 0.85 | TSHR (0.50) | MEN1KMT2ATSHRALDH1A1LMNA | |
| SCHEMBL24614982 | 0.84 | MEN1 (0.58) | MEN1KMT2AKDM5ALTA4HTSHR | |
| SCHEMBL26650890 | 0.81 | LTA4H (0.40) | KDM5ALTA4HDUTKDM4C | |
| SCHEMBL20168030 | 0.78 | TSHR (0.46) | MEN1KMT2ATSHRALDH1A1LMNA | |
| SCHEMBL30420680 | 0.78 | KDM4C (0.39) | KDM5ALTA4HALDH1A1KDM4C | |
| SCHEMBL14430424 | 0.78 | MEN1 (0.71) | MEN1KMT2AKDM5ALTA4HTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-2125757-A1 | MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008101665-A1 | MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | OAT, HAVCR2, CYP3A43 | MEN1 4723/4885KMT2A 3834/4885KDM5A 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.